Liu X, Hong L, Nilsson M, et al. - In a cohort of EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with osimertinib with or without concurrent use of aspirin, researchers assessed if improved clinical results can be achieved with the addition of aspirin. For this purpose, a retrospective investigation of MD Anderson Cancer Center GEMINI database was conducted to find 365 EGFR-mutant NSCLC patients who received osimertinib with or without concurrent use of aspirin. Significantly improved progression-free survival and overall survival were observed in patients in the aspirin-osimertinib group vs osimertinib group. Findings showed that central nervous system metastatic status, EGFR mutation type, age, gender, TP53, and PD-L1 status, an improved survival was offered by concurrent aspirin use with osimertinib in EGFR-mutant NSCLC patients.